Novavax, Inc.
Real-time prices from Yahoo Finance's public feed. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Latest news
All NVAX news ›Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies
A protein-vaccine developer with no fresh catalyst just posted a double-digit gain that dwarfs what Moderna and Merck managed in the same session, and the explanation reveals something uncomfortable about how this stock actually moves.…
Novavax (NVAX) Stock Pops 16% On Sanofi Vaccine News
Novavax stock climbed about 16% on October 9. The move pushed the biotech back toward the upper end of its 52-week range. The gain centers on fresh progress in Novavax’s partnership with Sanofi. Regulators in Belgium, Germany, and Portugal…
Novavax Inc (Coinbase Tokenized Stock) Analytics: Price Dynamics, Quarterly Returns, and Annual Price Changes in USD | CryptoRank.io
Novavax Inc (Coinbase Tokenized Stock) Analytics CryptoRank Novavax Inc (Coinbase Tokenized Stock) Analytics Novavax Inc (Coinbase Tokenized Stock) Quarterly Returns (USD) Novavax Inc (Coinbase Tokenized Stock) Monthly Returns (USD) NVAXc…
Novavax, Inc. $NVAX Stock Holdings Lessened by Shah Capital Management
Posted by Mitch Edgeman on Oct 9th, 2026 Novavax, Inc is a biotechnology company focused on the discovery, development and commercialization of vaccines. The company uses its recombinant protein-based vaccine platform and Matrix-M adjuvant…
Novavax: Vaccine Maker Sees Momentum In 2026, But Growth Story Holds Fundamental Risks
Novavax stock outlook: hold rating reaffirmed despite bullish Wall St. Sentiment seems volatile in this sector. Read here for more details on NVAX stock. - Novavax gets prior hold rating reaffirmed, challenging the bullish Wall St. view. -…
Novavax, Inc. Stock 12‑Month Price Target Raised to $14.86, Implies 35% Upside
TradingView Novavax, Inc. Stock 12‑Month Price Target Raised to $14.86, Implies 35% Upside - According to estimates from 7 analysts, Novavax, Inc. stock's average price target has risen from $14.71 to $14.86, with forecasts ranging from $7…
Novavax jumps 16% amid biotech rally, outpacing Moderna and Merck despite no new company news.
Novavax shares surged 16%, leading a biotech sector rally alongside Moderna's 11% gain and Merck's 3% rise. The spike occurred without any new company-specific announcements, driven by a broad sector-wide bid in vaccine and biotech stocks.…
Novavax and Moderna Shares Fall as Citi Assesses Vaccine Sector Volatility
Shares of Novavax Inc (NASDAQ:NVAX) and Moderna Inc (NASDAQ:MRNA) declined on Wednesday after both companies rose in the previous session following reports of a suspected pneumonic plague case in Russia. Novavax shares fell 11% after…
Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock
Cantor is acting as sole book runner for the offering. H.C. Wainwright & Co., Laidlaw & Company (UK) Ltd., Lucid Capital Markets, Maxim Group LLC, Roth Capital Partners and Titan Partners, a division of American Capital Partners are acting…
Nuvectis Pharma Announces Major Public Equity Offering
Nuvectis Pharma ( (NVCT) ) has shared an announcement. The most recent analyst rating on (NVCT) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on Nuvectis Pharma stock, see the NVCT Stock Forecast…
From articles in the 4Search news index.
In the news
People in the coverage
Most coverage from
-
finance.yahoo.com13
-
marketscreener.com8
-
theglobeandmail.com7
-
tradingview.com7
-
zacks.com6
Measured across the 4Savings news index. Headline tone is a simple word-based reading of the latest 93 headlines, not a forecast.